Open for inclusion

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase)

Cancer type: Glioblastoma

Phase: II

Principal Investigator: Brandal Petter

Country: NO

Keywords: Norway, Oslo, Glioblastoma, MGMT methylated

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02667587?term=ca209-548&rank=1